Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL

This work was supported by a grant from the Instituto de Salud Carlos III to APM PI22/01226, two grants from CRIS Cancer Foundation to Beat Cancer as part of the projects "Advanced Cell Therapy Unit Hospital Universitario La Paz" and JM "Proyecto Mateo: CAR T-cell therapy for juvenile myelomonocytic leukaemia" and "Terapia avanzada CAR-T CD19/CD22", Ayuda Nominativa de la Consejería de Investigación, Comunidad de Madrid, Spain. Work in MI lab was funded by a grant from the Spanish Ministry of Science and Innovation (PID2020-114148RB-I00). VGG was granted with Río Hortega (AES 2022 exp. Nº. CM22/00078) and Juan Rodés (AES 2024 exp. Nº. JR24/00003) contracts from the Carlos III Health Institute (ISCIII) through the European Funds of the Recovery, Transformation and Resilience Plan and financed by the European Union NextGenerationEU.

Authors

Institutions

Publication Details

Journal
EBioMedicine
Published
2025-08-01
DOI
https://doi.org/10.1016/j.ebiom.2025.105872
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL

Alicia Pernas-Sánchez, Rimas J. Orentas, Víctor Galán‐Gómez, Berta González‐Martínez et al.
EBioMedicine
CAR-T cell therapy research
article

Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL

Alicia Pernas-Sánchez, Rimas J. Orentas, Víctor Galán‐Gómez, Berta González‐Martínez, Elisa Izquierdo, Adela Escudero, Antonio Pérez‐Martínez, Halin Bareke, Pilar Guerra‐García, Isabel Mirones‐Aguilar, Marta Cobo, Elena Sánchez‐Zapardiel, Peirong Hu, Sonsoles San Román-Pacheco, Sara Naharro, Jordi Minguillón, Dina Schneider, Isabel Martínez-Romera, Manuel Izquierdo, Odelaisy León‐Triana, Carlos Echecopar, Andrés París‐Muñoz, Alfonso Navarro‐Zapata, Susana Vallejo, Alicia Martín-Ayuso
article en

Abstract

This work was supported by a grant from the Instituto de Salud Carlos III to APM PI22/01226, two grants from CRIS Cancer Foundation to Beat Cancer as part of the projects "Advanced Cell Therapy Unit Hospital Universitario La Paz" and JM "Proyecto Mateo: CAR T-cell therapy for juvenile myelomonocytic leukaemia" and "Terapia avanzada CAR-T CD19/CD22", Ayuda Nominativa de la Consejería de Investigación, Comunidad de Madrid, Spain. Work in MI lab was funded by a grant from the Spanish Ministry of Science and Innovation (PID2020-114148RB-I00). VGG was granted with Río Hortega (AES 2022 exp. Nº. CM22/00078) and Juan Rodés (AES 2024 exp. Nº. JR24/00003) contracts from the Carlos III Health Institute (ISCIII) through the European Funds of the Recovery, Transformation and Resilience Plan and financed by the European Union NextGenerationEU.

EBioMedicineVol. 118
Miltenyi Biotec (Germany) (DE), Hospital Universitario La Paz (ES), Spanish National Cancer Research Centre (ES), Instituto de Investigaciones Biomédicas Sols-Morreale (ES), Hospital La Paz Institute for Health Research (ES), Lentigen Technology (United States) (US), Universidad Autónoma de Madrid (ES)
Comunidad de Madrid, European Commission, Ministerio de Ciencia e Innovación, CRIS Cancer Foundation, Instituto de Salud Carlos III
Good health and well-being
Openalex Percentile: Top 72%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.